PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Incarda Therapeutics, Inc.

USPTO PatentsView assignee record - 11 granted patents across 5 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
11
Total patents granted
5
CPC technology areas
20.6
Avg claims per patent
+75%
5-year filing velocity

The verdict

Incarda holds 11 US patents across 5 technology areas, rank #24,550 of 50,000 tracked assignees.

#24,550
of 50,000 US assignees by volume
Top 63%
by Innovation Score (31.1/100)
20.6
avg claims per patent
+75%
filing velocity, last 5 yrs

Portfolio overview

Incarda Therapeutics, Inc. has been granted 11 US utility patents between 2015 and 2024, placing Incarda Therapeutics, Inc. at rank #24,550 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Incarda Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Incarda sits between Ignite Scalarc Solutions, Inc. (11 patents, rank #24,546) and Infinitum Solutions, Inc. (11 patents, rank #24,554) - the closest US assignees by grant volume. The composite Innovation Score of 31.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 4 in the 2015–2019 window, a +75% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Incarda Therapeutics, Inc.'s 20.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Incarda Therapeutics, Inc. against peers pursuing similar technology classes.

Who files at Incarda's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Incarda holds 11 patents at rank #24,550, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Incarda's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

31 Top 63% higher than 37% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 2015201820192020202120232024 1
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Incarda Therapeutics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 9.1%
2018 2 18.2%
2019 1 9.1%
2020 3 27.3%
2021 2 18.2%
2023 1 9.1%
2024 1 9.1%

Which technologies does Incarda Therapeutics, Inc. patent most?

Top 5 of 5 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#24,550

Across all tracked assignees

Innovation Score

31.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Incarda Therapeutics, Inc. hold?
Incarda Therapeutics, Inc. holds 11 US granted patents filed between 2015 and 2024, spanning 5 technology areas.
What is Incarda Therapeutics, Inc.'s Innovation Score?
Incarda Therapeutics, Inc. has an Innovation Score of 31.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Incarda Therapeutics, Inc. focus on?
Incarda Therapeutics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 11 patents. The company has filed patents in 5 CPC subclasses total.
Is Incarda Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Incarda Therapeutics, Inc.'s recent filing velocity is +75% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Incarda Therapeutics, Inc.'s patents?
Incarda Therapeutics, Inc.'s patents average 20.6 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Incarda Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Incarda's 11 grants land it in the top 63% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Incarda ranks #24,550 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.